Aprutumab Ixadotin is an antibody-drug conjugate (ADC) designed for targeted cancer therapy. It consists of a monoclonal antibody linked to a cytotoxic agent, allowing for selective delivery of the drug to cancer cells while minimizing damage to healthy tissues. The antibody component specifically binds to a target antigen expressed on the surface of certain tumor cells, facilitating internalization and subsequent release of the cytotoxic payload. This mechanism enhances the therapeutic efficacy against malignancies, particularly in cases where traditional chemotherapy may be less effective. Aprutumab Ixadotin has been investigated in clinical trials for its potential use in treating various types of cancer, including solid tumors. Its development reflects a growing trend in oncology towards personalized medicine, where treatments are tailored to the specific characteristics of an individual's cancer. As with many ADCs, the safety profile and potential side effects are important considerations, necessitating thorough clinical evaluation to establish optimal dosing and administration protocols.

Aprutumab Ixadotin

1708947-48-1: Aprutumab Ixadotin is an antibody-drug conjugate (ADC) designed for targeted cancer therapy. It consists of a monoclonal antibody linked to a cytotoxic agent, allowing for selective delivery of the drug to cancer cells while minimizing damage to healthy tissues. The antibody component specifically binds to a target antigen expressed on the surface of certain tumor cells, facilitating internalization and subsequent release of the cytotoxic payload. This mechanism enhances the therapeutic efficacy against malignancies, particularly in cases where traditional chemotherapy may be less effective. Aprutumab Ixadotin has been investigated in clinical trials for its potential use in treating various types of cancer, including solid tumors. Its development reflects a growing trend in oncology towards personalized medicine, where treatments are tailored to the specific characteristics of an individual's cancer. As with many ADCs, the safety profile and potential side effects are important considerations, necessitating thorough clinical evaluation to establish optimal dosing and administration protocols.

Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) targeting FGFR2, and is also the inaugural ADC to employ an auristatin-based active payload.

CAS 1708947-48-1

Aprutumab Ixadotin

Aprutumab ixadotin

Ref: TM-T9901A-230